Showing results (321-330 of 566) with videos related to

Sort By:
Pageof 57
Arthritis Care & Research|March 26, 2024
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 TrialVibeke Strand, Laure Gossec, Laura C Coates, et al.
RMD Open|March 12, 2016
Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain setUmut Kalyoncu, Alexis Ogdie, Willemina Campbell, et al.
The Journal of Rheumatology|July 5, 2011
Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest groupLaura C Coates, Aizad Mumtaz, Philip S Helliwell, et al.
Postgraduate Medicine|April 28, 2015
Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety studyRoy D Altman, Vibeke Strand, Marc C Hochberg, et al.
Nature Reviews. Disease Primers|February 9, 2018
Rheumatoid arthritisJosef S Smolen, Daniel Aletaha, Anne Barton, et al.
The Journal of Rheumatology|June 17, 2017
Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group ReportNatalia V Zamora, Robin Christensen, Niti Goel, et al.
RMD Open|February 5, 2019
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugsVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Arthritis Research & Therapy|December 17, 2015
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trialsVibeke Strand, Sima Ahadieh, Jonathan French, et al.
Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.
Arthritis Research & Therapy|April 9, 2020
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesCem Gabay, Gerd R Burmester, Vibeke Strand, et al.
Pageof 57